Acute alpha2 blockade by idazoxan increases insulin and lowers plasma glucose during positron emission tomography

Psychopharmacology Bulletin

Volumn 33, Issue 2, 1997, Pages 253-260

  Schmidt, Mark E ^a,c   Goldstein, David S ^a   Schouten, Jennifer L ^a   Matochik, John A ^b   Kim, Hyung Gun ^a   Potter, William Z ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Alpha2 adrenoceptor antagonist; Imidazoline; Norepinephrine; 18F fluoro deoxyglucose

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; IDAZOXAN;

ADRENERGIC SYSTEM; ADULT; ARTICLE; BLOOD VESSEL TONE; CLINICAL ARTICLE; DRUG RECEPTOR BINDING; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; NEUROTRANSMITTER RELEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BLOCKING;

EID: 0030788604     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Angel, I; Niddam, R; and Langer, SZ. Involvement of alpha-2 adrenergic subtypes in hyperglycemia. J. Pharmacol. Exp. Ther. 254:877-882, 1990.
2. Bacic, F.; McCarron, RM; Uematsu, S; and Spatz, M. Adrenergic receptors coupled to adenylate cyclase in human cerebromicrovascular endothelium. Metab. Brain Dis. 7:125-137, 1992.
3. 2 adrenergic receptor antagonist SL 84.0418 in healthy subjects. Clin. Pharmacol. Ther. 55:338-345, 1994.
4. 3H]idazoxan in the human cerebral cortex. Neurochem. Int. 2:153-163, 1993.
5. Brooks, RA; DiChiro, G; Zukerberg, BW; Bairamian, D; and Larson, SM. Test-retest studies of cerebral glucose metabolism using Fluorine-18 deoxyglucose: Validation of method. J. Nucl. Med. 28:53-59, 1987.
6. Brown, CA; Loweth, AC; Smith, SA; and Morgan, NG. Stimulation of insulin secretion by imidazoline compounds is not due to interaction with non-adrenoceptor idazoxan binding sites. Br. J. Pharmacol. 108:312-317, 1993.
7. Cappiello, A; McDougle, CJ; Mailson, RT; Heninger, GR; and Price, LH. Yohimbine augmentation of fluvoxamine in refractory depression: A single blind study. Biol. Psychiatry 38:765-767, 1995.
8. Chang, JY; Duara, R; Barker, W; Apicella, A; and Finn, R. Two behavioral states studied in a single PET/FDG procedure: Theory, method, and preliminary results. J. Nucl. Med. 28:852-860, 1987.
9. Charney, DS; Heninger, GR; and Breier, A. Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch. Gen. Psychiatry 41:751-763, 1984.
10. 2-adrenoceptors. Br. J. Pharmacol. 78:489-505, 1983.
11. Eisenhofer, G; Goldstein, DS; Stuhl, R; Keiser, HR; Sunderland, T; Murphy, DL; and Kopin, IJ. Simultaneous liquid chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma and their response to inhibition of monoamine oxidase. Clin. Chem. 32:2030-2033, 1986.
12. Elliot, HL; Jones, CR; Vincent, J; Lawrie, CB; and Reid, JL. The alpha adrenoceptor antagonist properties of idazoxan in normal subjects. Clin. Pharmacol. Ther. 36:190-196, 1984.
13. Flavahan, NA; Cooke, JP; Shepherd, JT; and Vanhoutte, PM. Human postjunctional alpha-1 and alpha-2 adrenoceptors: Differential distribution in arteries of the limbs. J. Pharm. Exp. Ther. 214:361-365, 1987.
14. Ghajar, JBG; Plum, F; and Duffy, TE. Cerebral oxidative metabolism and blood flow during acute hypoglycemia and recovery in unanesthetized rats. J. Neurochem. 38:397-409, 1982.
15. Goldstein, DS; Grossman, E; Listwak, S; and Folio, CJ. Sympathetic reactivity during a yohimbine challenge test in essential hypertension. Hypertension 18(5 Suppl.):III40-48, 1991.
16. 2-adrenoceptor-independent inhibition of noradrenaline release by imidazoline derivatives. NaunynSchmeideberg's Arch. Pharmacol 343:271-282, 1991.
17. 2-adrenoceptors in vascular sympathetic nerve endings in the human forearm. Circ. Res. 69:887-897, 1991a.
18. Grossman, E; Rea, RF; Hoffman, A; and Goldstein, DS. Yohimbine increases sympathetic nerve activity and norepinephrine spillover in normal volunteers. Am. J. Physiol. 260 (1 Pt 2):R142-R147, 1991b.
19. Gur, RC; Gur, RE; Resnick, SM; Skolnick, BE; Alavi, A; and Reivich, M. The effect of anxiety on cortical cerebral blood flow and metabolism. J. Cereb. Blood Flow Metab. 7:173-177, 1987.
20. John, GW; Doxey, JC; Walter, DS; and Reid, JL. The role of alpha- and beta-adrenoceptor subtypes in mediating the effects of catecholamines on fasting glucose and insulin concentrations in the rat. Br. J. Pharmacol. 100:699-704, 1990.
21. Kanetu, A; Miki, E; and Kosaka, K. Effect of beta and beta, adrenoceptor stimulants infused intrapancreatically on glucagon and insulin secretion. Endocrinology 97:1166-1173, 1975.
22. Kawazu, S; Suzuki, M; Negishi, K; Watanabe, T; and Ishii, J. Initial phase II clinical studies on midaglizole (DG-5128), a new hypoglycemic agent. Diabetes 36:221-226, 1987.
23. 2-adrenoceptors and of non-adrenergic idazoxan binding sites in pancreatic islets from young and adult hamsters. Int. J. Biochem. 25:1077-1083, 1993.
24. Lake, CR; Ziegler, MG; and Kopin, IJ. Use of plasma norepinephrine for evaluation of sympathetic neuronal function in man. Life Sci. 18:1315-1326, 1976.
25. Langer, SZ. Presynaptic regulation of the release of catecholamines. Biochem. Pharmacol. 23:1793-1800, 1974.
26. 2 antagonist, augments fluphenazine in schizophrenic patients: A pilot study. J. Clin. Psychopharmacol. 13:264-267, 1993.
27. McGrath, PJ; Rabkin, JG; Stewart, JW; Harrison, W; Quitkin, FM; and Markowitz, J. Placebo-controlled study of mianserin in depressed outpatients. Neuropsychobiol. 14:128-132, 1985.
28. Mefford, I; Caliguri, EJ; Grady, RK; Capella, P; Durkin, TA; and Chevalier, P. Microbore HPLC of biogenic amines in small biological samples. Methods in Enzymology 124:402-412, 1986.
29. Meneilly, GS; Cheung, E; and Tuokko, H. Altered responses to hypoglycemia of healthy elderly people. J. Clin. Endocrinol. Metab. 78:1341-1348, 1994.
30. Olpe, HR; Glatt, A; Laszlo, J; and Schellenberg, A. Some electrophysiological and pharmacological properties of the cortical, noradrenergic projection of the locus coeruleus in the rat. Brain Res. 186:9-19, 1980.
31. Osman, OT; Rudorfer, MV; and Potter, WZ. Idazoxan: A selective alpha2-antagonist and effective sustained antidepressant in two bipolar depressed patients (Letter). Arch. Gen. Psychiatry 46:958-959, 1989.
32. 2-adrenoceptor blockade does not enhance glucose-induced insulin release in normal subjects or patients with noninsulin-dependent diabetes. J. Clin. Endocrinol. Metab. 67:1054-1059, 1988.
33. Parini, A; Moudanos, CG; Pizzinat, N; and Lanier, SM. The elusive family of imidazoline binding sites. Trends Pharmacol. Sci. 17:13-16, 1996.
34. Peskind, ER; Raskind, MA; Wilkinson, CW; Flatness, DE; and Halter, JB. Peripheral sympathectomy and adrenal medullectomy do not alter cerebrospinal fluid norepinephrine. Brain Res. 367:258-264, 1986.
35. 2-adrenoceptors do not regulate catecholamine secretion by bovine adrenal chromaffin cells: A study with clonidine. Mol. Pharmacol. 29:134-141, 1986.
36. 2-adrenoceptors in human cerebral cortex. Naunyn-Schmeideberg's Arch. Pharmacol. 342:508-512, 1990.
37. Regunathan, S; Meeley, MP; and Reis, DJ. Expression of non-adrenergic imidazoline sites in chromaffin cells and mitochondrial membranes of bovine adrenal medulla. Biochem. Pharmacol. 45:1667-1675, 1993.
38. 2 adrenoceptor antagonist. Br. J. Clin. Pharmacol. 34:521-526, 1992.
39. Schmidt, ME; Ernst, M; Matochik, JA; Maisog, JM; Pan, BS; Zametkin, AJ; and Potter, WZ. Cerebral glucose metabolism during pharmacologic studies: Test-retest under placebo conditions. J. Nucl. Med. 37:1142-1149, 1996.
40. 2-adrenoceptor blockade. Neuropsychopharmacology 16:298-310, 1997a.
41. Schmidt, ME; Matochik, JA; Risinger, RC; Scheuten, JL; Zametkin, AJ; Cohen, RM; and Potter, WZ. Regional brain glucose metabolism following acute alpha-2 blockade by idazoxan. Clin. Pharmacol. Ther. 57:684-695, 1995.
42. 2-adrenoceptor blockade by idazoxan in healthy male and female volunteers. Psychoneuroendocrinology, in press, 1997b.
43. 2-adrenoceptor antagonist, MK-647, on the metabolic and cardiovascular response to exercise in healthy man. Br. J. Clin. Pharmacol. 37:39-44, 1994.
44. 2 receptor blockade facilitates the insulin response to adrenaline but not to glucose in man. Clin. Endocrin. 23:539-546, 1985.
45. Suda, S; Shinohara, M; Miyaoka, M; Lucignani, G; Kennedy, C; and Sokoloff, L. The lumped constant of the deoxyglucose method in hypoglycemia: Effects of moderate hypoglycemia on local cerebral glucose utilization in the rat. J. Cereb. Blood Flow Metab. 10:499-509, 1990.
46. Tuor, UI; Edvinsson, L; and McCulloch, J. Catecholamines and the relationship between cerebral blood flow and glucose use. Am. J. Physiol. 251 (4 Pt. 2):H824-H833, 1986.
47. van Veldhuizen, MJA; Feenstra, MGP; Heinsbroek, RPW; and Boer, GJ. In vivo microdialysis of noradrenaline overflow: Effects of alpha-adrenoceptor agonists and antagonists measured by cumulative concentration-response curves. Br. J. Pharmacol. 109:655-660, 1993.
48. Vartiainen, H, and Leinenen, E. Double-blind study of mirtazapine and placebo in hospitalized patients with major depression. Eur. Neuropsychopharmacol. 4:145-150, 1994.